Company registration number 14496144 (England and Wales)
GONMISOL UK LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
GONMISOL UK LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 7
GONMISOL UK LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
6
114,937
72,170
Current assets
Stocks
166,957
298,217
Debtors
7
798,478
439,463
Cash at bank and in hand
589,268
544,553
1,554,703
1,282,233
Creditors: amounts falling due within one year
8
(1,635,213)
(1,331,362)
Net current liabilities
(80,510)
(49,129)
Total assets less current liabilities
34,427
23,041
Provisions for liabilities
(29,428)
-
0
Net assets
4,999
23,041
Capital and reserves
Called up share capital
9
1
1
Profit and loss reserves
4,998
23,040
Total equity
4,999
23,041

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 15 September 2025 and are signed on its behalf by:
Daniel Minguez
Anthony Weston
Director
Director
Company registration number 14496144 (England and Wales)
GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
1
Accounting policies
Company information

Gonmisol UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is 1st Floor Gallery Court, 28 Arcadia Avenue, London, N3 2FG.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:

 

 

The financial statements of the company are consolidated in the financial statements of Suan Farma Holding, S.L. These consolidated financial statements are available from its registered office, Registro Mercantil de Madrid, Calle Principe de Vergara, 72, 28006, Madrid (Spain).

1.2
Going concern

The financial statements are prepared on a going concern basis.true

 

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. It is the director's assessment that the company continues to be a going concern and that no material uncertainties exist as a result of going concern.

 

Accordingly, the assets and liabilities have been valued on the basis that the company will continue in business.

GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 3 -
1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

IT equipment
5 years straight-line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.8
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.  If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.9
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 5 -
3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Executive Director(employee)
1
-
Executive Directors (not employed by the Company):
2
1
Total
3
1

Their aggregate remuneration comprised:

2024
2023
£
£
Wages and salaries
55,000
-
0
Social security costs
4,542
-
Pension costs
16,417
-
0
75,959
-
0

Of the Company’s directors, only Mr Weston was employed by the Company in 2024. The remaining directors (Executive Directors (not employed by the Company)) were not employees of the Company, as they are employed by other Group entities .

 

4
Directors' remuneration
2024
2023
£
£
Remuneration paid to directors
71,417
-
0
5
Taxation
2024
2023
£
£
Deferred tax
Changes in tax rates
29,428
-
0
GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 6 -
6
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2024
76,158
Additions
65,234
At 31 December 2024
141,392
Depreciation and impairment
At 1 January 2024
3,988
Depreciation charged in the year
22,467
At 31 December 2024
26,455
Carrying amount
At 31 December 2024
114,937
At 31 December 2023
72,170
7
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
234,818
191,022
Amounts owed by group undertakings
558,382
247,773
Other debtors
5,278
668
798,478
439,463
8
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
142,447
89,082
Amounts owed to group undertakings
1,492,188
1,204,608
Taxation and social security
578
37,672
1,635,213
1,331,362
9
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
1 Ordinary share of £1 of 0p each
1
1
1
1
GONMISOL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
10
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

Senior Statutory Auditor:
Paul Winter
Statutory Auditor:
Taylor Associates
Date of audit report:
15 September 2025
11
Events after the reporting date

On 30 July 2025, a fixed charge was registered over the Company’s bank accounts in favour of Ares Management Limited. This security was granted as part of the Group’s wider financing arrangements and therefore also serves as a cross-guarantee of Group borrowings. The charge does not give rise to additional liabilities in the Company’s balance sheet as at 31 December 2024.

12
Related party transactions

The company has taken advantage of the exemption permitted by FRS 102 Section 33 Related Party Disclosures, not to provide disclosures of transactions entered into with other wholly owned members of the group.

13
Parent and Ultimate parent undertaking

The company's parent and ultimate parent is Archimed SAS domiciled in Lyon, France.

 

These financial statements are consolidated in Suan Farma Holding, S.L. The registered office address is Registro Mercantil de Madrid, Calle Principe de Vergara, 72, 28006, Madrid (Spain).

2024-12-312024-01-01falsefalsefalse15 September 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityLuca D'AmbrosioyCarlos CurtoDaniel MinguezAnthony Weston144961442024-01-012024-12-31144961442024-12-31144961442023-12-3114496144core:OtherPropertyPlantEquipment2024-12-3114496144core:OtherPropertyPlantEquipment2023-12-3114496144core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3114496144core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3114496144core:CurrentFinancialInstruments2024-12-3114496144core:CurrentFinancialInstruments2023-12-3114496144core:ShareCapital2024-12-3114496144core:ShareCapital2023-12-3114496144core:RetainedEarningsAccumulatedLosses2024-12-3114496144core:RetainedEarningsAccumulatedLosses2023-12-3114496144core:ShareCapitalOrdinaryShareClass12024-12-3114496144core:ShareCapitalOrdinaryShareClass12023-12-3114496144bus:Director32024-01-012024-12-3114496144bus:Director42024-01-012024-12-3114496144core:ComputerEquipment2024-01-012024-12-31144961442022-12-212023-12-3114496144core:OtherPropertyPlantEquipment2023-12-3114496144core:OtherPropertyPlantEquipment2024-01-012024-12-3114496144core:WithinOneYear2024-12-3114496144core:WithinOneYear2023-12-3114496144bus:OrdinaryShareClass12024-01-012024-12-3114496144bus:OrdinaryShareClass12024-12-3114496144bus:OrdinaryShareClass12023-12-3114496144bus:PrivateLimitedCompanyLtd2024-01-012024-12-3114496144bus:FRS1022024-01-012024-12-3114496144bus:Audited2024-01-012024-12-3114496144bus:Director12024-01-012024-12-3114496144bus:Director22024-01-012024-12-3114496144bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3114496144bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP